Alessandro Csermely

TL;DR: In this paper, the authors performed a meta-analysis of observational studies to quantify the magnitude of the association between non-alcoholic fatty liver disease (NAFLD) and risk of incident CVD events.

TL;DR: A large and updated meta-analysis of observational studies indicates that NAFLD is significantly associated with a~1.45-fold increased long-term risk of incident CKD stage ≥3.

TL;DR: In this paper, a systematic review and meta-analysis of randomized controlled trials (RCTs) was performed to assess the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for treatment of nonalcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH).

TL;DR: In this paper, the authors performed a meta-analysis of observational studies to quantify the magnitude of the association between non-alcoholic fatty liver disease (NAFLD) and risk of extrahepatic cancers.

TL;DR: In this paper, the authors systematically searched three electronic databases (up to 31 October 2020) for identifying placebo-controlled or head-to-head RCTs that used SGLT-2 inhibitors for treatment of NAFLD.